Deutsche Bank Maintains 'Sell' Rating on AstraZeneca Despite Positive Drug Data
Despite positive data for its drug tozorakimab in treating chronic obstructive pulmonary disease (COPD), Deutsche Bank has maintained a 'sell' rating on AstraZeneca. The broker cited strong clinical results from the OBERON and TITANIA trials, as well as encouraging feedback during an investor call by analyst Emmanuel Papadakis. These findings support tozorakimab's commercial potential with peak sales guidance raised above $5 billion. AstraZeneca also reported positive preliminary data for its drug Imfinzi in small cell lung cancer maintenance treatment. However, Deutsche Bank viewed these developments as only a minor positive and not enough to justify buying the stock at current levels. The broker noted that consensus forecasts remain around $4 billion by 2030, with potential for modest upward revisions if analysts reassess peak revenue expectations following detailed COPD findings.
Tickers: $AZN
Topics: AstraZeneca COPD data Deutsche Bank analysis sales forecasts tozorakimab